Dyne Therapeutics seeks FDA accelerated approval for muscular dystrophy drug
Dyne Therapeutics (NASDAQ:DYN) submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration seeking conditional marketing clearance for z-rostudirsen, its investigational treatment targeting a specific subset of patients with Duchenne muscular dystrophy (DMD).
The Waltham, Massachusetts-based company is pursuing the regulatory agency's Accelerated Approval pathway for the therapy, also designated as DYNE-251.
The filing proposes a therapeutic regimen consisting of a 20 mg/kg intravenous infusion administered once every four weeks.
If granted Priority Review by regulators, Dyne anticipates a commercial launch in the United States could occur as early as the first quarter of 2027.
The submission is tailored for Duchenne patients whose underlying genetic mutations are amenable to exon 51 skipping—a mechanism designed to bypass errors in the genetic code and allow cells to produce a truncated but functional variant of the vital muscle protein dystrophin.
Duchenne muscular dystrophy is a progressive, fatal neuromuscular disease driven by a near-total lack of this structural protein.
Dyne’s regulatory package hinges on data derived from the registrational expansion cohort of its global Phase 1/2 DELIVER clinical trial.
According to the company's data, z-rostudirsen achieved a statistically significant increase in the production of dystrophin, satisfying the surrogate endpoint criteria utilized for the regulatory filing.
The study also demonstrated functional stabilization and gains across several motor and cardiopulmonary endpoints alongside a favorable adverse-event profile.
To support the transition toward standard, full market approval and fulfill international regulatory requirements, Dyne recently initiated its Phase 3 FORZETTO trial, which will serve as the necessary confirmatory study.
Beyond its lead asset, the clinical-stage firm is leveraging its molecular delivery platform to advance four additional preclinical exon-skipping candidate compounds aimed at other genetic mutations within the Duchenne patient population.
